Targeted replacement of endogenous T cell receptors
US11033584B2 · kind B2 · utility
7Cited by
10References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2019 |
| Grant date | Jun 15, 2021 |
| Priority date | — |
| Expiry date | Sep 11, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)-β chain and a heterologous TCR-α chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.